Table 1. Tumor incidence and tumor invasion area within reproductive tracts.
Treated 9 months with estrogen
|
Treated first 6 of 9 months with estrogen
|
|||||||
---|---|---|---|---|---|---|---|---|
Genotype | No. of mice with cancer* (%) | Avg. no. of cancers per mouse | Total area of tumor invasion per mouse, mm2 | Largest area of tumor invasion per mouse, mm2 | No. of mice with cancer* (%) | Avg. no. of cancers per mouse | Total area of tumor invasion per mouse, mm2 | Largest area of tumor invasion per mouse, mm2 |
Nontransgenic | 1/15 (6) | 0.067 ± 0.26 | 0.029 ± 0.11 | 0.029 ± 0.11 | 0/12 (0) | — | — | — |
K14E7 | 11/11 (100) | 6.6 ± 3.6 | 18 ± 13 | 13 ± 11 | 5/18 (38) | 0.54 ± 0.78 | 2.1 ± 3.6 | 2.0 ± 3.4 |
K14E6/K14E7 | 6/6 (100) | 7.0 ± 2.9 | 49 ± 26 | 37 ± 21 | 9/11 (82) | 1.3 ± 0.79 | 6.3 ± 7.9 | 5.0 ± 6.4 |